An interview with: Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France PARIS, France—A clinical trial using a personalized therapeutic vaccine, that
An interview with:
Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France
PARIS, France—A clinical trial using a personalized therapeutic vaccine, that recognizes multiple genetic features of each patient’s tumor, brought durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancers, and also prevented relapse in some patients.
At the 2024 Annual Meeting of the American Association for Cancer Research, held in San Diego, California, Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory at the Institut Curie in Paris, gave the Audio Journal of Oncology the latest update on his findings with the “neoantigen vaccine”.
AACR 2024 Abstract Number: LB401
ABSTRACT TITLE: Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
Related Episodes
More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths
An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce
Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere
An interview with: Adam Thiesen, PhD Candidate, UConn Health, University of Connecticut and the Jackson Laboratory for Genomic Medicine, Farmington, CT And with: Jayesh Desai MD, Medical Oncologist,
Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer
An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institut